Press release issued on 01.03.2004

Helsinn's Top Management announces the
go-live of the new product web site :
www.oxaprozin.net
 

March, 01 2004

Helsinn's Top Management is delighted to announce the go-live of a web site focused on our product Oxaprozin, a
non-steroidal, anti-inflammatory drug particularly effective in the symptomatic treatment of osteoarticular diseases including osteoarthritis, rheumatoid arthritis, ankylosing spondilitis, muscoloskeletal pain and acute gout, which, due to its pharmacokinetic properties, can be administered once daily and, thanks to its positive risk-benefit profile, can be considered the drug of choice in its approved indications.

The site, which can be reached either at www.oxaprozin.net or through the Licensing/Products section of our company web site www.Helsinn.com, contains general as well as scientific information and links relative to this patient-oriented NSAID.